A Digital Active Aging Training Program for Older Adults
NCT06270862, Not applicable, Unknown, Toronto Metropolitan University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Digital Active Aging Training Program for Older Adults | ClinicalTrials.gov |
| NCT number | NCT06270862 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 240 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Toronto Metropolitan University | ClinicalTrials.gov |
| Conditions | Healthy Aging, Cognitive Change, Psychological Stress, Loneliness, Social Interaction | ClinicalTrials.gov |
| Interventions | Resilience training, cognitive training, physical exercise, social interaction, workshop series | ClinicalTrials.gov |
| First posted | 2024-02-21 | ClinicalTrials.gov |
| Last updated | 2024-05-01 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Exercise Self-efficacy level (ESES) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 40) higher score means better self-efficacy at carrying out regular physical activities and exercise. | ClinicalTrials.gov |
| Primary | the 5-item World Health Organization WellBeing Index (WHO-5) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 25) higher score indicates better overall self-perception of wellbeing in the past 2 weeks | ClinicalTrials.gov |
| Primary | Kessler Psychological Distress Scale (K10) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 50) higher score indicates worse overall mental health | ClinicalTrials.gov |
| Primary | Multidimensional Scale of Perceived Social Support (MSPSS) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 7) higher score indicates higher levels of self-precepted social support | ClinicalTrials.gov |
| Primary | Conner-Davidson Resilience Scale 10-item (CD RISC-10) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 40) higher score indicates higher resilience in face of difficulty in life. | ClinicalTrials.gov |
| Primary | Emotional regulation Questionnaire (ERQ) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | Cognitive reappraisal (out of 42) and expressive suppression (out of 28). Higher score indicates higher inclination to use this facet to control their emotions. | ClinicalTrials.gov |
| Primary | Positive and Negative Affect Schedule (PANAS) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | Positive affect (out of 50) and negative affect (out of 50). Higher score indicates feelings of higher levels of the positive/negative affect at the moment. | ClinicalTrials.gov |
| Primary | Visual working memory test | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | Assessed using computerized games from CogniFit. Higher score indicates better visual short-term memory and memory span. | ClinicalTrials.gov |
| Primary | Divided attention test | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | Assessed using computerized games from CogniFit. Higher score indicates better ability to divide attention between two competing tasks. | ClinicalTrials.gov |
| Primary | Visual memory test | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | Assessed using computerized games from CogniFit. Higher score indicates better ability to memorize and recognize shapes and sequence order of visual object. | ClinicalTrials.gov |
| Primary | Stroop test | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | Assessed using computerized games from CogniFit. Higher score indicates better ability to inhibit irrelevant information in tasks. | ClinicalTrials.gov |
| Primary | Sustained attention to response test | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | Assessed using computerized games from CogniFit. Higher score indicates better ability to sustain attention to show rapid response to targets when present. | ClinicalTrials.gov |
| Secondary | Satisfaction with life scale (SWLS) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 35) higher score indicates higher self-perception of life satisfaction | ClinicalTrials.gov |
| Secondary | Instrumental Activities of Daily Living(IADL) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 8) higher score indicates better ability to carry out daily physical activity | ClinicalTrials.gov |
| Secondary | The 6-item De Jong Gierveld Loneliness Scale | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | (out of 30) higher score indicates higher levels of loneliness | ClinicalTrials.gov |
| Secondary | The Brief Approach/Avoidance Coping Questionnaire (BACQ) | (1) pre-test (2) through study completion, an average of 1 month (3) 1-month post study completion | approach (out of 30) and avoidance (out of 30) scores. Higher score in each category indicates their inclination to act in relation to problems and illness. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 25
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 3299702 | BACKGROUND | PubMed |
| 5349366 | BACKGROUND | PubMed |
| 7726811 | BACKGROUND | PubMed |
| 12214795 | BACKGROUND | PubMed |
| 16367493 | BACKGROUND | PubMed |
| 18696313 | BACKGROUND | PubMed |
| 19144968 | BACKGROUND | PubMed |
| 22132328 | BACKGROUND | PubMed |
| 25874889 | BACKGROUND | PubMed |
| 26005337 | BACKGROUND | PubMed |
| 31056641 | BACKGROUND | PubMed |
| 31394984 | BACKGROUND | PubMed |
| 32199471 | BACKGROUND | PubMed |
| 32215365 | BACKGROUND | PubMed |
| 32275292 | BACKGROUND | PubMed |
| 32514427 | BACKGROUND | PubMed |
| 33033099 | BACKGROUND | PubMed |
| 33104409 | BACKGROUND | PubMed |
| 33328958 | BACKGROUND | PubMed |
| 35649300 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Sustained Attention to Response | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)